Biogen Reports First Quarter 2015 Revenues of $2.6 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Biogen (BIIB) Price Target Lifted to $422 at UBS Despite Caution on Tecfidera Estimates
April 27, 2015 10:41 AM EDTUBS analyst Matthew Roden reiterated a Neutral rating but raised his price target on Biogen (NASDAQ: BIIB) to $422.00 (from $350.00) following Q1 results. While they remain cautious on expected revisions to Tecfidera estimates they are positive on AD.
Roden's key takeaways from the call:
[1] Gross to net adjustments were higher this quarter for Tecfidera in part... More
Biogen (BIIB) Weakness Overdone, Buy Pullback: BMO
April 24, 2015 3:32 PM EDTBMO Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $511. The stock dropped over 6% after the company reported Q1 results that missed consensus. In the view of analyst Jim Birchenough, weakness is overdone and represents a buying opportunity.
"We are reaffirming... More
Biogen (BIIB) Misses Q1 EPS by 6c; Revs Light
April 24, 2015 7:01 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $3.82, versus the analyst estimate of $3.88. Revenue for the quarter came in at $2.56 billion versus the consensus estimate of $2.66 billion.
First Quarter 2015 Performance Highlights
Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in the same quarter last year.TECFIDERA revenues... More